• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by SCYNEXIS Inc.

    1/8/25 1:46:31 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SCYX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 14)


    SCYNEXIS, INC.

    (Name of Issuer)


    COMMON STOCK

    (Title of Class of Securities)


    811292200

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    811292200


    1Names of Reporting Persons

    Federated Hermes, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6,428,250.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    6,428,250.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,428,250.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    15.50 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    811292200


    1Names of Reporting Persons

    Voting Shares Irrevocable Trust
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6,428,250.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    6,428,250.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,428,250.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    15.50 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    811292200


    1Names of Reporting Persons

    Thomas R. Donahue
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,428,250.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,428,250.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,428,250.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    15.50 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    811292200


    1Names of Reporting Persons

    Ann C. Donahue
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,428,250.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,428,250.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,428,250.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    15.50 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    811292200


    1Names of Reporting Persons

    J. Christopher Donahue
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,428,250.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,428,250.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,428,250.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    15.50 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    SCYNEXIS, INC.
    (b)Address of issuer's principal executive offices:

    1 Evertrust Plaza, 13th Floor Jersey City, NJ 07302-6548
    Item 2. 
    (a)Name of person filing:

    Federated Hermes, Inc.
    (b)Address or principal business office or, if none, residence:

    1001 Liberty Avenue, Pittsburgh, PA 15222-3779
    (c)Citizenship:

    Pennsylvania
    (d)Title of class of securities:

    COMMON STOCK
    (e)CUSIP No.:

    811292200
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    6,428,250
    (b)Percent of class:

    15.50  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    6,428,250

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    6,428,250

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See Exhibit "1" Attached
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Federated Hermes, Inc.
     
    Signature:/s/J. Christopher Donahue
    Name/Title:J. Christopher Donahue, as President of Federated Hermes, Inc.
    Date:01/08/2025
     
    Voting Shares Irrevocable Trust
     
    Signature:/s/Thomas R. Donahue
    Name/Title:Thomas R. Donahue, as Trustee of Voting Shares Irrevocable Trust
    Date:01/08/2025
     
    Signature:/s/Ann C. Donahue
    Name/Title:Ann C. Donahue, as Trustee of Voting Shares Irrevocable Trust
    Date:01/08/2025
     
    Signature:/s/J. Christopher Donahue
    Name/Title:J. Christopher Donahue, as Trustee of Voting Shares Irrevocable Trust
    Date:01/08/2025
     
    Thomas R. Donahue
     
    Signature:/s/Thomas R. Donahue
    Name/Title:Thomas R. Donahue
    Date:01/08/2025
     
    Ann C. Donahue
     
    Signature:/s/Ann C. Donahue
    Name/Title:Ann C. Donahue
    Date:01/08/2025
     
    J. Christopher Donahue
     
    Signature:/s/J. Christopher Donahue
    Name/Title:J. Christopher Donahue
    Date:01/08/2025

    Comments accompanying signature:  SEE EXHIBITS 2 AND 3 ATTACHED Exhibit Information EXHIBIT 1 ITEM 3 CLASSIFICATION OF REPORTING PERSONS EXHIBIT 2 AGREEMENT FOR JOINT FILING OF SCHEDULE 13G EXHIBIT 3 POWER OF ATTORNEY
    Get the next $SCYX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SCYX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SCYX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Angulo Gonzalez David bought $27,400 worth of shares (20,000 units at $1.37), increasing direct ownership by 4% to 507,871 units (SEC Form 4)

      4 - SCYNEXIS INC (0001178253) (Issuer)

      9/16/24 8:00:27 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCYX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Angulo Gonzalez David was granted 23,000 shares, increasing direct ownership by 3% to 816,598 units (SEC Form 4)

      4 - SCYNEXIS INC (0001178253) (Issuer)

      4/10/25 8:02:09 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Angulo Gonzalez David was granted 18,800 shares, increasing direct ownership by 2% to 793,598 units (SEC Form 4)

      4 - SCYNEXIS INC (0001178253) (Issuer)

      3/20/25 7:39:22 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Legal Officer Sukenick Scott was granted 92,511 shares, increasing direct ownership by 27% to 436,706 units (SEC Form 4)

      4 - SCYNEXIS INC (0001178253) (Issuer)

      1/27/25 4:05:22 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCYX
    SEC Filings

    See more
    • SEC Form DEFA14A filed by SCYNEXIS Inc.

      DEFA14A - SCYNEXIS INC (0001178253) (Filer)

      4/30/25 4:03:33 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by SCYNEXIS Inc.

      DEF 14A - SCYNEXIS INC (0001178253) (Filer)

      4/30/25 4:01:58 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by SCYNEXIS Inc.

      10-K - SCYNEXIS INC (0001178253) (Filer)

      3/12/25 4:55:31 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCYX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for BREXAFEMME issued to SCYNEXIS, INC

      Submission status for SCYNEXIS, INC's drug BREXAFEMME (ORIG-1) with active ingredient IBREXAFUNGERP has changed to 'Approval' on 06/01/2021. Application Category: NDA, Application Number: 214900, Application Classification: Type 1 - New Molecular Entity

      6/2/21 11:20:46 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for BREXAFEMME issued to SCYNEXIS, INC

      Submission status for SCYNEXIS, INC's drug BREXAFEMME (SUPPL-1) with active ingredient IBREXAFUNGERP has changed to 'Approval' on 06/01/2021. Application Category: NDA, Application Number: 214900, Application Classification: Type 1 - New Molecular Entity

      6/2/21 9:57:42 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCYX
    Financials

    Live finance-specific insights

    See more

    $SCYX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $SCYX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $SCYX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection

      Brexafemme complements GSK's industry-leading infectious disease portfolio with an FDA approved treatment for vulvovaginal candidiasisSCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royaltiesSCYNEXIS retains rights to all other assets derived from enfumafungin, with GSK having a right of first negotiation to these pre-clinical and discovery stage assetsSCYNEXIS to host an investor call and webcast at 8:30 a.m. EDT today LONDON and JERSEY CITY, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- GSK plc (NYSE:GSK) and SCYNEXIS, Inc. (NASDAQ:SCYX), today announced they have entered into an exclusive licence agreement for Brexafemme (i

      3/30/23 7:05:00 AM ET
      $GSK
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SCYNEXIS Reports Third Quarter 2022 Financial Results and Provides Corporate Update

      SCYNEXIS recently announced new strategic direction to refocus its resources on the clinical development of ibrexafungerp for severe, hospital-based indications.Ivor Macleod, a 30-year biopharma veteran, joined SCYNEXIS as Chief Financial Officer.Marco Taglietti, M.D., to retire as President and Chief Executive Officer of SCYNEXIS and step down from the Board of Directors on December 31, 2022. David Angulo, M.D., Chief Medical Officer of SCYNEXIS will become President and Chief Executive Officer and join the Board effective January 1, 2023.BREXAFEMME® (ibrexafungerp tablets) prescriptions continued to grow in Q3 2022, increasing 13% over Q2 2022, generating net revenues of $1.6 million in Q3

      11/9/22 7:00:00 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SCYNEXIS to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 9

      JERSEY CITY, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at 8:30 a.m. EDT on Wednesday, November 9, 2022, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2022. Conference call and webcast details: Investors (domestic): (844) 826-3033Investors (international): (412) 317-5185Webcast:  LinkConference ID: 10172836 A live audio webcast can be accessed by visiting the Investor Relations section of the Company'

      11/1/22 8:30:00 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aegis Capital reiterated coverage on SCYNEXIS with a new price target

      Aegis Capital reiterated coverage of SCYNEXIS with a rating of Buy and set a new price target of $35.00 from $40.00 previously

      6/7/21 9:58:05 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aegis Capital reiterated coverage on SCYNEXIS with a new price target

      Aegis Capital reiterated coverage of SCYNEXIS with a rating of Buy and set a new price target of $40.00 from $45.00 previously

      4/12/21 12:54:40 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group reiterated coverage on SCYNEXIS with a new price target

      Maxim Group reiterated coverage of SCYNEXIS with a rating of Buy and set a new price target of $22.00 from $17.00 previously

      2/17/21 2:23:39 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

      JERSEY CITY, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second-generation fungerp candidate SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) in Vienna, Austria being held from April 11-15, 2025. SCY-247 is being developed to address systemic fungal diseases, with a key focus on invasive fungal infections where resistance to current limited treatment options is a significant concern. These presentations at ESCMID Global

      4/8/25 8:00:00 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

      The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in Q3 of 2025.Four presentations for SCY-247 were accepted by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) congress, April 11-15, 2025 in Vienna, Austria.SCYNEXIS continues to make progress towards the restart of the Phase 3 MARIO study in invasive candidiasis. The Company anticipates the restart, pending the FDA's lifting of the clinical hold, in the second quarter of 2025.SCYNEXIS ended 2024 with cash, cash equivalents and investments of $75.1 million, and projects a cash runway into Q3 2026. JERSEY CITY, N.J

      3/12/25 5:08:56 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

      JERSEY CITY, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has completed the dosing of the first cohort of subjects in its Phase 1 trial of SCY-247, the Company's second-generation triterpenoid antifungal in development for the treatment of severe invasive fungal infections.   "We are pleased to advance our potent, second-generation fungerp candidate SCY-247 into the clinic in a Phase 1 study," said David Angulo, M.D., President and Chief Executive Officer. "SCY-247 has consistently shown promising results in prec

      12/18/24 8:00:00 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

      SC 13G/A - SCYNEXIS INC (0001178253) (Subject)

      11/14/24 7:07:26 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

      SC 13G/A - SCYNEXIS INC (0001178253) (Subject)

      11/6/24 8:56:32 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

      SC 13G/A - SCYNEXIS INC (0001178253) (Subject)

      10/7/24 1:38:20 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCYX
    Leadership Updates

    Live Leadership Updates

    See more
    • AUROBAC THERAPEUTICS welcomes two new independent members to its Board: Manos Perros, as Chairman, and Marco Taglietti

      Lyon - France, July 24, 2023 (GLOBE NEWSWIRE) -- AUROBAC THERAPEUTICS WELCOMES TWO NEW INDEPENDENT MEMBERS TO ITS BOARD: MANOS PERROS, AS CHAIRMAN, AND MARCO TAGLIETTI Dr Manos Perros and Dr Marco Taglietti are appointed new Independent Members of the Board of AUROBAC THERAPEUTICSDr Perros becomes Chairman of the Board These new appointments bring extensive US and international experience in company leadership and development of anti-infectives from R&D to commercialization Lyon (France), Thursday July 24, 2023 AUROBAC THERAPEUTICS SAS, a biopharmaceutical company developing the next generation of products to fight antimicrobial resistance (AMR), is delighted to announce th

      7/24/23 8:00:00 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SCYNEXIS Reports First Quarter 2021 Financial Results and Provides Corporate Update

      Secured non-dilutive funding of approximately $35 million thus far in 2021, including licensing payments from Hansoh Pharma, the first tranche from a term loan agreement with Hercules and Silicon Valley Bank, and the monetization of the 2020 New Jersey NOLsAppointed Christine Coyne as Chief Commercial Officer to lead the launch of ibrexafungerp (Brexafemme®) for the treatment of vaginal yeast infections, following expected approval by June 1st Began dosing patients in a Phase 1 trial of the IV formulation of ibrexafungerpFurther strengthened balance sheet and projected cash runway into 2023 JERSEY CITY, N.J., May 17, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology c

      5/17/21 8:30:00 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SCYNEXIS Appoints Accomplished Commercial Executive Christine Coyne as Chief Commercial Officer to Lead the Brexafemme® Launch

      Strengthening the management team with deep anti-infective commercial expertise across hospital and community settings ahead of anticipated approval of Brexafemme (ibrexafungerp) in June 2021 and H2:2021 launch JERSEY CITY, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the appointment of Christine Coyne as Chief Commercial Officer, effective May 10, 2021. Ms. Coyne will play a significant role in the anticipated U.S. launch and commercialization of Brexafemme, the expected trade name for ibrexafungerp, an oral antifungal p

      5/11/21 8:30:00 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care